Theravance Biopharma Inc. held its Annual General Meeting of Shareholders on May 19, 2025. The meeting included the election of Class II directors, with Rick E Winningham, Jeremy T. Grant, Susannah Gray, and Donal O'Connor being elected to the board. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. All proposals presented at the meeting were approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-051050), on May 20, 2025, and is solely responsible for the information contained therein.